#USA #biotechnology #Newton #Lumicell #Cheryl Blanchard

Lumicell Welcomes Dr. Cheryl R. Blanchard to Its Board of Directors

In a significant move that underscores its commitment to innovation in cancer detection, Lumicell, Inc., a pioneering company in fluorescence-guided imaging technologies, has announced the appointment of Dr. Cheryl R. Blanchard to its Board of Directors. This strategic addition is expected to enhance Lumicell’s leadership as it continues to make strides in the field of medical technology, particularly in the realm of onco-surgery.

Who is Dr. Cheryl R. Blanchard?

Dr. Blanchard is a well-respected figure within the biotech and medtech landscape, and her appointment brings over 30 years of experience in building and transforming both public and private life sciences companies. Most recently, she took the helm as President, CEO, and Director at Anika Therapeutics, a leading player in regenerative orthopedic products. During her tenure there, she successfully executed a growth strategy that involved divesting non-core assets and enhancing the company’s footprint in innovative pain management solutions for osteoarthritis.

Her extensive background also includes leadership roles such as CEO at Microchips Biotech and Senior Vice President and Chief Scientific Officer at Zimmer Biomet. Her rich experience combined with a strong scientific background positions her as an invaluable asset to Lumicell.

What Lumicell Stands For

Established with a robust mission to revolutionize intraoperative cancer detection, Lumicell has developed proprietary fluorescence imaging technology that has already gained FDA approval for use in breast cancer treatments. The company is currently exploring expanding its technology for various solid tumors, indicating a proactive approach toward transforming the standard of care in oncology.

Andrey J. Zarur, Ph.D., Co-Founder and Chairman of the Board, expressed enthusiasm about Dr. Blanchard’s joining: "Cheryl brings a unique blend of scientific insight, commercial leadership, and board experience. Her proven track record in launching category-defining products and transforming organizations aligns perfectly with our goals at Lumicell."

A New Chapter in Cancer Care

Dr. Blanchard's goals align with Lumicell’s vision of patient-focused innovation, emphasizing the importance of bringing advanced surgical solutions to the market. "Lumicell's technology has the potential to significantly elevate care standards in cancer surgery," said Dr. Blanchard upon her appointment. "I am honored to join the board at this pivotal moment and am eager to support Lumicell as it embarks on its next growth phase."

Her engagement with various boards, including those of Vigil Neuroscience and Daré Bioscience, reflects a broad and active involvement in advancing life sciences. Furthermore, Dr. Blanchard’s esteemed membership in the National Academy of Engineering and her position as a Fellow of the American Institute for Medical and Biological Engineering highlight her recognition and respect within the industry.

Looking Ahead

With Dr. Blanchard on board, Lumicell is poised to leverage her strategic acumen to enhance its existing initiatives and potentially accelerate the integration of their technologies into mainstream surgical practices. Her leadership is expected to play a crucial role in steering the company’s project developments, especially as they aim to bring their transformative LumiSystem™ to more surgeons and patients.

By marrying cutting-edge technology with compassionate care, Lumicell is not merely improving medical procedures; it is redefining the patient experience in surgical oncology. The journey ahead looks promising as they navigate the intricate landscape of cancer detection and treatment with seasoned leaders guiding their path.